Introduction
Topiramate is an effective antiepileptic drug for seizure [1] and migraine [2] . As other antiepileptic drug, topiramate posed the adverse effect of central nervous system, such as drowsiness and mental suppression. However, topiramate has two unusual nonneurological side effects: urolithiasis [3] [4] [5] and body weight loss [6, 7] . Topiramate can cause metabolic acidosis through the inhibition of carbonic anhydrase. The risk of urolithiasis may be increased through the increased urinary pH, urinary bicarbonate excretion in patients receiving topiramate [8] .
Studies for urolithiasis in patients receiving topiramate were limited to case reports, case series [3] [4] [5] 9] , and biochemical characteristics that favor stone formation [8, 10, 11] . So far, there was no observational cohort study that compares the risk of urolithiasis in patients receiving and not receiving topiramate. The aim of the study was to investigate topiramate associated urolithiasis using a nationwide population-based cohort.
Methods

Database
We extracted data from a sampling longitudinal subset of National Health Insurance Research Dataset (NHIRD). The NHIRD contains all claim data that covered over 99% of the total population in Taiwan (approximately 23.72 million individuals). The sampling longitudinal subset, published by National Health Research Institute of Taiwan, contained the ambulatory service and hospitalization records of 1,000,000 individuals. The subset was randomly sampled from the NHIRD and was divided into 25 equal groups. There is no significant difference in distribution of age and gender between the patients in the subset and the original NHIRD. All the personal identifiers were encrypted before published. The confidentiality was assured by the data regulations of the Bureau of National Health Insurance.
Study sample
We analyzed all patients who took topiramate (ATC code N03AX11) between January 1, 1997 and December 31, 2008 in the NHIRD subset (n = 1880). Patients treated with topiramate less than 30 days (n = 503) were excluded. The analyzed cohort consisted 1377 patients receiving topiramate and 1377 control patients. Most of the patients took topiramate for seizure or migraine. The control patients were selected from patients who were not receiving topiramate and were matched for their age, gender, and year of enrollment.
Study design
The earliest date of topiramate prescribed was recorded as an index date. In control patients, the index date was defined as the date of first visit. Each patient was individually tracked from the index date to the last ambulatory service visit. Urolithiasis events were defined using ICD-9-CM code 592.x for kidney or ureter stone, 594.x for bladder and urethra stone, and 602.0 for prostate stone. A history of urolithiasis was defined as patients with urolithiasis diagnosed before the index date. The end of observation was defined as the date of urolithiasis diagnosed or the last ambulatory service visit if no urolithiasis identified. The time from index date to the end of observation was recorded for urolithiasis free survival analysis. Gouty arthritis was defined as ICD-9-CM code 274.x. In patients who took topiramate, duration and total dosage of topiramate were calculated.
Statistical analysis
Data are reported as mean AE SD for normally distributed variables, median and interquartile range for not normally distributed continuous variables, or percent frequency for categorical variables.
Pearson x 2 tests were used to determine the differences in categorical variables. The risk of urolithiasis was analyzed using Kaplan-Meier analysis with log-rank test. Variables that may be associated with urolithiasis were analyzed using Cox proportional hazard regression and hazard ratios (HRs) and 95% confidence interval (CI) were calculated. A p value lower than 0.05 was considered statistically significant. All statistical analyses were performed using SAS statistical package, version 9.1 (SAS, Inc., NC, USA).
Results
Patients' age and the proportion of male gender were not different in patients receiving topiramate and the control patients (Table 1) . Of the patients receiving topiramate, 46 (3.3%) patients developed urolithiasis in 2.3 (1.3-4.3) years. The percentage of patients who developed urolithiasis was not different to that (2.4%) of the control patients (p = 0.138). The duration of follow-up, the proportion of patients with a history of urolithiasis, and the proportion of patients with gouty arthritis in patients who took topiramate were not different from that of control patients. The urolithiasis free survival ( Fig. 1) was not different in patients receiving topiramate and the control patients (p = 0.166, log-rank test). In multivariable Cox regression for possible risk factors of urolithiasis (Table 2) , the use of topiramate was not associated with a higher risk of urolithiasis (p = 0.13). A history of urolithiasis was the most important risk factors for the development of urolithiasis with a HR of 17.78 (95% CI: 11.12-28.43, p < 0.01). Patients' age was significantly associated with the risk of urolithiasis and the HR was 1.13 (95% CI: 1.00-1.28, p = 0.04) for every 10 additional years. Male gender and a history of gout arthritis were not associated with the risk of urolithiasis.
In patients receiving topiramate (Table 3) , patients with urolithiasis were older (p = 0.009), more likely to be male (p = 0.049), and more likely to have a history of urolithiasis (p < 0.001). The duration and the total dosage of topiramate were not different in patients with and without urolithiasis. In patients receiving topiramate, a history of urolithiasis was associated with the risk of urolithiasis (Table 4 ) with an aHR of 10.45 (95% CI: 5.17-21.22, p < 0.001). Male patients were associated with a higher risk of urolithiasis (p = 0.049) with an aHR of 1.87 (95% CI: 1.00-3.49). The duration of topiramate had no effect on the risk of urolithiasis (p = 0.482) and the total dosage of topiramate was not associated with increased risk for urolithiasis (p = 0.751).
Discussion
This is the first observational cohort study in investigating the risk of urolithiasis in patients receiving topiramate. We found that Data was expressed as mean AE standard deviation (SD) or n percentage as appropriate. topiramate was not associated with increased risk of urolithiasis. This conclusion was supported by four findings. First, the proportion of patients who developed urolithiasis was similar in patients receiving topiramate and the control patients (Table 1) . Second, the urolithiasis free survival curve was not different in patients receiving topiramate and control patients (Fig. 1) . Third, the use of topiramate was not associated with higher urolithiasis in multivariable Cox regression (Table 2) . Fourth, the duration and total dosage of topiramate were not associated with increased risk of urolithiasis (Table 3) . The large patient number was one of the major strength of this study. The development of urolithiasis can be summarized in three pathways [12] : overgrowth on interstitial apatite plaque such as idiopathic calcium oxalate stone, crystal deposits in renal tubules, and free solution crystallization such as cystinuria or hyperoxaluria. Overgrowth on interstitial apatite plaque may be the pathway responsible for the development of urolithiasis in patients receiving topiramate [5, 10, [12] [13] [14] [15] [16] . In the pathway, the increased urinary oxalate [8, 11, 14] may deposit on the plaque and increase the sizes of the stones. Larger stones were easier to be identified in X-ray or ultrasound in clinical settings. However, information regarding the component of the stone was not available and we were not able to investigate this hypothesis.
Among the variables analyzed, a history of urolithiasis was the most powerful predictor of urolithiasis (Tables 2 and 4 ) and was associated with a ten-fold increase of risk of urolithiasis. In a subgroup analysis of patients with a history of urolithiasis, all variables including age, sex, and gout were not associated with the risk of urolithiasis. In 151 patients with a history of urolithiasis, topiramate was not associated with increased risk of urolithiasis (p = 0.355). The analysis of patients with a history of urolithiasis may provide better adjustments for the confounders that were not available in the NHRID such as family history [17] , diet [18, 19] and anatomical abnormalities associated with stone formation [20] . Since information of treatments and the results of treatment (if the stone was removed) of urolithiasis were not available in the NHRID, it is not possible to identify if these urolithiasis were recurrent stones or residual stone after incomplete treatment.
There were some potential limitations of the study. First, performance bias cannot be completely avoided as clinicians may be aware of the possible adverse effect of topiramate and, therefore, perform more tests. This may increase the chance of urolithiasis found in patients receiving topiramate. In contrast, urolithiasis in control patients may be left unnoticed until it was found accidently or diagnosed when the patents developed certain symptoms associated with urolithiasis. Second, urolithiasis was identified using ICD-9-CM code and this may under-estimate the prevalence of urolithiasis [21] . The under-estimation of urolithiasis may have a limited effect on the result because the underestimated incidence of urolithiasis affected both patients receiving topiramate and control patients. Third, the diagnosis of urolithiasis may be not made in uniform measurements because urolithiasis was defined using ICD-9-CM code. A diagnosis of urolithiasis can be made based on the findings of computer tomography, X-ray, ultrasound, or clinical manifestations such as flank pain, gross hematuria, and no signs of urinary tract infection. Despite of the limitations, this study was the only cohort study for urolithiasis in patients taking topiramate. Patients with urolithiasis were excluded in most of the randomized controlled trials [2, 22, 23] and the development of urolithiasis was not recorded in these randomized controlled trials.
In conclusion, topiramate may not be associated with increased risk for urolithiasis in an observational nationwide cohort study. The duration of topiramate and the total dosage of topiramate had no effect on stone formation in patients treated with topiramate.
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